Literature DB >> 29119277

Priority of lymph node dissection for proximal gastric cancer invading the greater curvature.

Yukio Maezawa1,2, Toru Aoyama1,2, Takanobu Yamada1,2, Kazuki Kano1,2, Tsutomu Hayashi2, Tsutomu Sato2, Takashi Oshima2, Yasushi Rino2, Munetaka Masuda2, Takashi Ogata1, Haruhiko Cho1,2, Takaki Yoshikawa3,4.   

Abstract

BACKGROUND: The therapeutic efficacy of dissection of the splenic hilar lymph nodes (#10) has not been fully evaluated in locally advanced proximal gastric cancer (LAGC) invading the greater curvature of the stomach.
METHODS: Patients with LAGC invading the greater curvature who underwent D2 total gastrectomy with splenectomy between January 2000 and May 2015 were retrospectively examined. The therapeutic value index was calculated by multiplying the metastatic rate of a station and the 5-year survival of patients with metastasis to that station; the metastatic rate and the index of each lymph node station were then compared.
RESULTS: In total, 82 patients were eligible for the present study. The most frequent metastatic node was #3, followed by #1, #4d and #7, #2, #4sa and #10, and #4sb and #9. These lymph nodes had a metastatic rate of more than 10%. The node station with the highest index was #3, followed by #7, #4d, #1, #4sb, #4sa, #2, and #9. The index of #10 was lower, but exceeded those of #8a and #11p.
CONCLUSIONS: The metastatic rate of #10 was relatively high at 13%, and the therapeutic value index was as high as those of other suprapancreatic nodes. D2 dissection for proximal cancer located in the greater curvature should include removal of node #10.

Entities:  

Keywords:  Gastric cancer; Greater curvature; Metastatic rate; Therapeutic index

Mesh:

Year:  2017        PMID: 29119277     DOI: 10.1007/s10120-017-0775-9

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  8 in total

1.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

2.  Progress in gastric cancer surgery in Japan and its limits of radicality.

Authors:  K Maruyama; K Okabayashi; T Kinoshita
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

3.  New method to evaluate the therapeutic value of lymph node dissection for gastric cancer.

Authors:  M Sasako; P McCulloch; T Kinoshita; K Maruyama
Journal:  Br J Surg       Date:  1995-03       Impact factor: 6.939

4.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

5.  Type-oriented therapy for gastric cancer effective for lymph node metastasis: management of lymph node metastasis using activated carbon particles adsorbing an anticancer agent.

Authors:  T Takahashi; K Sawai; A Hagiwara; S Takahashi; K Seiki; H Tokuda
Journal:  Semin Surg Oncol       Date:  1991 Nov-Dec

6.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

7.  Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma.

Authors:  Takeshi Sano; Mitsuru Sasako; Junki Mizusawa; Seiichiro Yamamoto; Hitoshi Katai; Takaki Yoshikawa; Atsushi Nashimoto; Seiji Ito; Masahide Kaji; Hiroshi Imamura; Norimasa Fukushima; Kazumasa Fujitani
Journal:  Ann Surg       Date:  2017-02       Impact factor: 12.969

8.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  8 in total
  11 in total

1.  Reappraise role of No. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: a pooled analysis of 4 prospective trial.

Authors:  Qing Zhong; Qi-Yue Chen; Yan-Chang Xu; Gang Zhao; Li-Sheng Cai; Guo-Xin Li; Ze-Kuan Xu; Su Yan; Zu-Guang Wu; Fang-Qin Xue; Yi-Hong Sun; Dong-Po Xu; Wen-Bin Zhang; Jin Wan; Pei-Wu Yu; Jian-Kun Hu; Xiang-Qian Su; Jia-Fu Ji; Zi-Yu Li; Jun You; Yong Li; Lin Fan; Chao-Hui Zheng; Jian-Wei Xie; Ping Li; Chang-Ming Huang
Journal:  Gastric Cancer       Date:  2020-07-26       Impact factor: 7.370

2.  Clinical Relevance of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer: A Propensity Score-Matching Case-Control Study.

Authors:  Jian-Xian Lin; Zu-Kai Wang; Ying-Qi Huang; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ze-Ning Huang; Ju-Li Lin; Hua-Long Zheng; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  Ann Surg Oncol       Date:  2021-03-25       Impact factor: 5.344

3.  Different risks of nodal metastasis by tumor location in remnant gastric cancer after curative gastrectomy for gastric cancer.

Authors:  Kazuya Takahashi; Takaki Yoshikawa; Shinji Morita; Takahiro Kinoshita; Masahiro Yura; Sho Otsuki; Masanori Tokunaga; Yukinori Yamagata; Akio Kaito; Hitoshi Katai
Journal:  Gastric Cancer       Date:  2019-07-13       Impact factor: 7.370

4.  Is Splenic Hilar Lymph Node Dissection Without Splenectomy Essential for Proximal Advanced Gastric Cancer?

Authors:  Yoon Jung Oh; Deok Hee Kim; Bang Wool Eom; Hong Man Yoon; Young-Woo Kim; Keun Won Ryu
Journal:  Ann Surg Oncol       Date:  2021-07-17       Impact factor: 5.344

5.  Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based on propensity matching.

Authors:  Ze-Ning Huang; Wen-Wu Qiu; Cheng-Hao Liu; Qi-Yue Chen; Chao-Hui Zheng; Ping Li; Jia-Bin Wang; Jian-Xian Lin; Jun Lu; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ju-Li Lin; Hua-Long Zheng; Guang-Tan Lin; Chang-Ming Huang
Journal:  Gastric Cancer       Date:  2021-08-13       Impact factor: 7.701

6.  Limited Clinical Significance of Splenectomy and Splenic Hilar Lymph Node Dissection for Type 4 Gastric Cancer.

Authors:  Aina Kunitomo; Kazunari Misawa; Yuichi Ito; Seiji Ito; Eiji Higaki; Seiji Natsume; Takashi Kinoshita; Tetsuya Abe; Koji Komori; Yasuhiro Shimizu
Journal:  J Gastric Cancer       Date:  2021-12-27       Impact factor: 3.720

Review 7.  The 140 years' journey of gastric cancer surgery: From the two hands of Billroth to the multiple hands of the robot.

Authors:  Masanori Terashima
Journal:  Ann Gastroenterol Surg       Date:  2021-02-12

8.  Risk factors of lymph node metastasis in the splenic hilum of gastric cancer patients: a meta-analysis.

Authors:  Jun Du; Yangchao Shen; Wenwu Yan; Jinguo Wang
Journal:  World J Surg Oncol       Date:  2020-09-01       Impact factor: 2.754

Review 9.  Disadvantages of Complete No. 10 Lymph Node Dissection in Gastric Cancer and the Possibility of Spleen-Preserving Dissection: Review.

Authors:  Tetsuro Toriumi; Masanori Terashima
Journal:  J Gastric Cancer       Date:  2020-02-27       Impact factor: 3.720

Review 10.  Advantages of Splenic Hilar Lymph Node Dissection in Proximal Gastric Cancer Surgery.

Authors:  Ali Guner; Woo Jin Hyung
Journal:  J Gastric Cancer       Date:  2020-03-20       Impact factor: 3.720

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.